Anyone who suffered a heart attack, stroke or cardiovascular event after using a low-T drug like AndroGel, Axiron or AndroDerm is urged to visit DrugRisk or speak with a lawyer about their legal rights as soon as possible.
New York, NY (PRWEB) March 25, 2014
The prescription drug safety advocates at DrugRisk.com have added the latest information to the site for testosterone warnings and legal news. Experts have called for new warnings on popular low-T drugs after studies show they may cause heart attacks or stroke*.
DrugRisk is a free resource providing the latest warnings, safety alerts, recalls and litigation news to those taking popular prescription drugs. Visitors can see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
Last year, more than 5.5 million men filled prescriptions for low-T drugs like AndroGel, Axiron and AndroDerm**. However, recent studies question their safety.
DrugRisk has added research from the National Institutes of Health and UCLA showing those over 65 or with a history of heart disease using low-T drugs had double the rate of heart attack***. Last year, the AMA cautioned the same patients may face a 29% increased rate of heart attacks, stroke or death from low-T drugs****
Most recently, DrugRisk learned the Endocrine Society has asked that testosterone replacement therapy drugs undergo new and larger safety tests in order to identify risks*.
Some patients have already filed a testosterone lawsuit in federal court alleging drugs like AndroGel caused heart attack or stroke without warning*****. Lawyers are offering help to those affected.
Anyone who suffered a heart attack, stroke or cardiovascular event after using a low-T drug like AndroGel, Axiron or AndroDerm is urged to visit DrugRisk or speak with a lawyer about their legal rights as soon as possible. DrugRisk only recommends lawyers who have already handled testosterone lawsuits.
For more information on the research, side effects and litigation news related to testosterone drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Endocrine Society, 2/7/14; endocrine.org/news-room/current-press-releases/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks
**Bloomberg, 1/31/14; bloomberg.com/news/2014-01-31/heart-attack-risk-of-testosterone-drugs-under-u-s-review.html
***Public Library of Science, 1/29/14; plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805
****JAMA 11/5/13; media.jamanetwork.com/news-item/testosterone-therapy-following-coronary-angiography-associated-increased-risk-adverse-outcomes/
*****Bloomberg, 2/5/14; bloomberg.com/news/2014-02-05/abbott-labs-sued-by-five-men-claiming-androgel-injuries.html; Aurecchia v. AbbVie Inc., 14-cv-00772, U.S. Dist. Ct, Northern District of Illinois (Chicago); Marino v. AbbVie Inc., 14-cv-00777 U.S. Dist. Ct, Northern District of Illinois (Chicago)